Maria Grammoustianou

Dr. Maria Grammoustianou

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
ITIoannis P Trontzas
Ioannis P Trontzas
IVIoannis Vathiotis
Ioannis Vathiotis
CEChristina Economidou
Christina Economidou
IPIoulia Petridou
Ioulia Petridou
GGGeorgia Gomatou
Georgia Gomatou
ESEkaterini Syrigou
Ekaterini Syrigou
Background: SARS-CoV-2 mortality rates are significantly higher in patients with lung cancer compared with the general population. However, little is known on their immunization status after vaccination. Methods: To evaluate the humoral response (seroconversion) of patients with lung cancer following vaccination against SARS-COV-2 (Group A), we obtained antibodies against SARS-CoV-2 spike (S) protein both at baseline and at different time points after the first dose of SARS-CoV-2 vaccine (two to three weeks [T1], six weeks ± one week [T2], 12 weeks ± three weeks [T3], and 24 weeks ± three weeks [T4]). Antibodies were also acquired from a control cohort of non-lung cancer patients (Group B) as well as a third cohort containing healthy controls (Group C) at all time points and at T4, respectively, to make comparisons with Group A. Analysis of antibody response at different time points, association with clinicopathologic parameters, and comparisons with control groups were performed. Results: A total of 125 patients with lung cancer were included in the analysis (96 males [74.3%], median age of 68 years [46–91]. All study participants received two vaccine doses (BNT162b2, mRNA-1273, AZD1222). Analysis of anti-SARS-CoV-2 S antibody titers showed minimal response at T1 (0.4 [0.4–48.6] IU/mL). Antibody response peaked at T2 (527.0 [0.4–2500] IU/mL) and declined over T3 (323.0 [0.4–2500] IU/mL) and T4 (141.0 [0.4–2500] IU/mL). Active smokers had lower antibody titers at T2 (p = 0.04), T3 (p = 0.04), and T4 (p < 0.0001) compared with former or never smokers. Peak antibody titers were not associated with any other clinicopathologic characteristic. No significant differences were observed compared with Group B. However, lung cancer patients exhibited significantly decreased antibody titers compared with Group C at T4 (p < 0.0001). Conclusions: Lung cancer patients demonstrate sufficient antibody response six weeks after the first dose of vaccine against SARS-CoV-2 when vaccinated with two-dose regimens. Rapidly declining antibody titers six weeks after the first dose underline the need for a third dose three months later, in patients with lung cancer, and especially active smokers.

8 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
MGMaria Grammoustianou
Maria Grammoustianou
FDFoteinos-Ioannis Dimitrakopoulos
Foteinos-Ioannis Dimitrakopoulos
AKAngelos Koutras
Angelos Koutras
Breast cancer is the most common cancer type in women. The vast majority of breast cancer patients have hormone receptor-positive (HR+) tumors. In advanced HR+ breast cancer, the combination of endocrine therapy with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors is considered the standard of care in the front-line setting. Nevertheless, resistance to hormonal therapy and CDK4/6 inhibitors eventually occurs, leading to progression of the disease. Antibody–drug conjugates (ADCs) comprise a promising therapeutic choice with significant efficacy in patients with HR+ breast cancer, which is resistant to endocrine treatment. ADCs typically consist of a cytotoxic payload attached by a linker to a monoclonal antibody that targets a specific tumor-associated antigen, offering the advantage of a more selective delivery of chemotherapy to cancer cells. In this review, we focus on the ADC mechanisms of action, their toxicity profile and therapeutic uses as well as on related biomarkers and future perspectives in advanced HR+ breast cancer.

23 September 2025 in eClinicalMedicine
Verified
Journal Article
Open access
MGMaria Grammoustianou
Maria Grammoustianou
SMStefano Maccarone
Stefano Maccarone
EGEmma Gillanders
Emma Gillanders
GMGwenn Menvielle
Gwenn Menvielle
MPMarie Preau
Marie Preau
MFMaria Alice Franzoi
Maria Alice Franzoi
Diverse population inclusion in clinical research is essential for generating high-quality, generalizable data that promotes health equity. However, clinical research often underrepresents elderly individuals, minoritised ethnicities, and marginalized socio-demographic groups. Implicit and explicit biases among healthcare providers can create barriers to equitable participation in clinical trials, affecting patient care, clinical outcomes, and provider-patient trust. Bias-focused interventions have been reported, yet methodological inconsistencies and limited generalizability of studies hinder their effectiveness. This systematic review synthesizes global evidence on interventions designed to address healthcare provider biases, identifying intervention components, trends, outcomes assessed and gaps in the current literature. Following PRISMA guidelines, a systematic review of English-language peer-reviewed studies published between 2004 and June 2025 was conducted. The review included both quantitative and qualitative studies assessing interventions targeting healthcare provider biases or cultural competency. A comprehensive search of Scopus, Cochrane, and PubMed MEDLINE databases identified 110 studies. Study quality, risk of bias, and outcomes were assessed using the RoB-2 tool for randomized trials and ROBINS-I for non-randomized studies (PROSPERO ID: CRD42024515985). Among the 103 studies assessed for efficacy, 75.7% reported positive outcomes. The majority of studies (69%) were conducted in the U.S. Most interventions combined educational and experiential methods, with the majority being brief (up to 3 h). An increase in the use of digital delivery methods was observed in the past 5 years, with 45% of studies incorporating digital components, particularly after 2020. Key outcomes included explicit bias (53.6%), cultural competency (31.2%), and implicit bias (31.8%), measured mainly by heterogeneous and non-standardized instruments. Notably, only 38 studies (34.5%) assessed actual healthcare provider behavior, and 30 studies (27.2%) evaluated long-term efficacy. High risk of bias and methodological challenges impacted the quality of evidence. This review highlights positive short-term effects of interventions on implicit bias and cultural competence but suggests future research could benefit from more rigorous trial designs, standardized metrics for measuring efficacy, and actual provider behavior. It also emphasizes the need for more implementation research to identify barriers and facilitators for scaling interventions to ensure their sustainability and broader impact on diversity, equity, and inclusion in healthcare and research. This project is funded by WeShare, DIVERSIFY and SIRIC Epicure projects. WeShare program is supported by the French State, managed by the 10.13039/501100001665 Agence Nationale de la Recherche under the Investissements Program integrated into France 2030, with reference number: ANR-21-ESRE-0017. DIVERSIFY is funded by La 10.13039/501100004099 Ligue Contre le Cancer . SIRIC Epicure is funded by INCA-DGOS-Inserm-ITMO Cancer 18002.

8 April 2024 in Cancers
Verified
Journal Article
Open access
PDF file
Marousa KouvelaMarousa Kouvela
Marousa Kouvela
MLMaria Effrosyni Livanou
Maria Effrosyni Livanou
DSDimitra Theodore Stefanou
Dimitra Theodore Stefanou
IVIoannis Vathiotis
Ioannis Vathiotis
FSFotini Sarropoulou
Fotini Sarropoulou
NSNIKOLAOS SYRIGOS
NIKOLAOS SYRIGOS
Background: The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk. Methods: This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested. Results: In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not (p = 0.26 and p = 0.32, respectively). Conclusion: Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.

1 June 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MKMarousa Kouvela
Marousa Kouvela
MGMaria Grammoustianou
Maria Grammoustianou
FSFoteini Sarropoulou
Foteini Sarropoulou
MMMaria Mani
Maria Mani
IGIoannis Gkiozos
Ioannis Gkiozos
KSKostas N. Syrigos
Kostas N. Syrigos
E13531 Background: It is known that malignancies exaggerate the risk of thrombosis up to 20%, while for Lung Cancer (LC) is articulated up to 14%. Likewise, thrombosis amplifies the LC progression, thrombosis-associated lung cancer (TALC). The pathophysiology promoting LCAT & TALC is multifactorial depending on the characteristics of LC, specific anti-cancer modalities, patient features, and biomarkers such as tissue factor, neutrophil extracellular traps released in response to cancer, cancer procoagulant, and cytokines. Low-molecular-weight heparins are used in prophylaxis and treatment for high-burden for thrombosis (HTB) patients, allowing specialists to focus on the cancer disease. Methods: iCaLT is a prospective observational study conducted in Thoracic Diseases General Hospital Sotiria (Athens, Greece) assessing the role of thromboprophylaxis with tinzaparin 10.000 Anti-Xa IU, OD with the systemic anti-cancer therapy (SACT). LC patients with active disease that are currently under treatment are enrolled after signing informed consent and monitored up to six months or until anticoagulation terminates. Results: Results from 106 patients reported, 29 (27%) are still ongoing: 79% were males. Histological results involve: adenocarcinomas 54%, squamous 25%, small cell 15%and others. LC patients received SACT: 55%, 23%, 10%, 6% in 1st, 2nd, 3rdand 4th line. HTB patients with active LC related to 4 factors: disease, treatment, biomarker and patient features are presented in table. On average patients accumulated 3.7±1.1risk factors, 91% of patients accumulated ≥3 risk factors. Median thromboprophylaxis duration was: 4.8 months (1st-3rd quartile: 2.8-6.0 months). One patient experienced thrombotic event in lower extremes and consequently pulmonary embolism (efficacy 99.1%, 95%CI: 94.6-99.8%), five patients experienced minor bleeding adverse events (haemoptysis) (4.7%, 95%CI: 2.0-10.6%), and two patients allergic reactions. Patients with haemoptysis had lower age (60 vs. 67, p=0.1357). Conclusions: Thromboprophylaxis with tinzaparin intermediate dose in high thrombotic burden patients with active lung cancer is effective and safe. Further research is needed.[Table: see text]